HDM201 and Pazopanib in Patients With P53 Wild-type Advanced/Metastatic Soft Tissue Sarcomas
Status:
Not yet recruiting
Trial end date:
2025-07-01
Target enrollment:
Participant gender:
Summary
This trial is a two-step Phase I/II study comprising:
Part 1: A dose escalation part with the aim to assess the safety of the proposed combination
(N= up to 30 patients). In the dose escalation part, eligible patients will be treated with a
fixed dose of pazopanib and escalating doses of HDM201.
Part 2: An extension part to collect preliminary data about the clinical activity of the
proposed combination according to the 6M-PFR.